Epitalon and the telomere research
There is peer-reviewed literature. Most of it is from Russian institutions. Here's what it actually says.
TL;DR
- Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from a pineal gland extract called epithalamin; its most-cited research involves telomerase activation in vitro.
- The human evidence base is predominantly from Russian clinical investigations conducted in the 1990s and 2000s; no large-scale US trials have been completed.
- FDA removed epitalon from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
What it is
Epitalon is a four-amino-acid peptide — alanine, glutamic acid, aspartic acid, glycine — derived from epithalamin, a polypeptide extract from bovine pineal gland. It was developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, whose research group has published much of the literature on this compound. The initial hypothesis was that the pineal gland produces peptides involved in biological aging, and that supplementing these peptides might modulate aging-related processes. The focus of the most-cited research has been on telomerase activity and telomere length — markers associated with cellular aging — though the clinical relevance of those laboratory observations is still debated.
How it works
Telomeres are protective caps on the ends of chromosomes that shorten with each cell division. Telomerase is an enzyme that can extend telomere length. In vitro research by Khavinson's group, published in Bulletin of Experimental Biology and Medicine (2003), reported that epitalon induced telomerase activity in human fetal fibroblasts and somatic cells. The proposed mechanism is that epitalon influences chromatin structure, potentially upregulating telomerase reverse transcriptase (hTERT) expression. These observations are from cell cultures; the translation to human physiology in vivo has not been established through rigorous controlled trials outside the Russian research context.
Who asks about it
Epitalon appears frequently in longevity-focused discussions, particularly among people who have encountered the telomere-aging narrative and want to act on it. Telomere length as a biomarker of biological age has attracted mainstream attention, which makes epitalon appealing as a purported intervention. The mismatch between the theory's intuitive appeal and the thinness of the independent human evidence is worth naming directly.
What the research says
Beyond the in vitro telomerase data, Khavinson's group published observational studies in Russian clinical populations reporting associations between epithalamin/epitalon treatment and reduced all-cause mortality in elderly cohorts over 12–15 year follow-up periods. These studies were published primarily in Russian journals with English abstracts on PubMed, and have not been replicated by independent research groups in Western clinical settings. A search of ClinicalTrials.gov finds no registered US Phase I or II trials for epitalon as of this writing. The gap between the claims and the independent evidence is substantial.
What to know before considering it
The regulatory status is the immediate practical issue. FDA removed epitalon from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, epitalon is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding epitalon to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. Additionally, any compound that activates telomerase requires thoughtful risk consideration, since uncontrolled telomerase activity is a characteristic of cancer cells; the relationship between therapeutic telomere extension and cancer risk is not resolved in the literature.
The Halftime POV
Epitalon sits at an interesting but genuinely uncertain place in longevity science. The telomere angle is conceptually compelling, and Khavinson's decades of research represent a real body of work — just one that hasn't been independently replicated at scale. Intellectual honesty requires holding both of those facts at once. When clearer data and legal access arrive together, this will be worth revisiting.
Related reading:
FAQ
Q: What is Epitalon? A: Epitalon (also called Epithalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin. Research on it originates primarily from Russian scientists, particularly the work of Vladimir Khavinson. It has been studied in vitro for telomerase activation and in animal models for longevity-related endpoints.
Q: What does the published research show about Epitalon and telomeres? A: Published in vitro research describes telomerase activation in human cell lines following Epitalon exposure, primarily from Russian and Eastern European research groups. Animal studies have examined lifespan and tumor incidence. Human clinical trial data meeting Western randomized controlled trial standards is essentially absent as of this writing.
Q: Is Epitalon available through a US compounding pharmacy? A: FDA removed Epitalon from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Epitalon is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Epitalon to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Epitalon is available from online vendors as a 'research use only' compound — a designation that means it is not approved for human use and carries no sterility, purity, or dosing guarantees.
Disclaimer
Epitalon was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Khavinson VKh et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." — Bull Exp Biol Med, 2003
- Khavinson V et al. "Peptide regulation of aging." — Adv Gerontol, 2011
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Epitalon?
Epitalon (also called Epithalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin. Research on it originates primarily from Russian scientists, particularly the work of Vladimir Khavinson. It has been studied in vitro for telomerase activation and in animal models for longevity-related endpoints.
What does the published research show about Epitalon and telomeres?
Published in vitro research describes telomerase activation in human cell lines following Epitalon exposure, primarily from Russian and Eastern European research groups. Animal studies have examined lifespan and tumor incidence. Human clinical trial data meeting Western randomized controlled trial standards is essentially absent as of this writing.
Is Epitalon available through a US compounding pharmacy?
FDA removed Epitalon from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Epitalon is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Epitalon to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Epitalon is available from online vendors as a 'research use only' compound — a designation that means it is not approved for human use and carries no sterility, purity, or dosing guarantees.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.